- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Gene therapy for polygenic or complex diseases ; volume:12 ; number:1 ; day:4 ; month:9 ; year:2024 ; pages:1-29 ; date:12.2024
Biomarker Research ; 12, Heft 1 (4.9.2024), 1-29, 12.2024
- Urheber
-
Wu, Tingting
Hu, Yu
Tang, Liang V.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s40364-024-00618-5
- URN
-
urn:nbn:de:101:1-2411202152527.825922714154
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 15.08.2025, 07:37 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Wu, Tingting
- Hu, Yu
- Tang, Liang V.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Venous Thromboembolism in Kidney Diseases and Genetic Predisposition
Acute Total Occlusion of the Abdominal Aorta in an Elderly Patient with Atrial Fibrillation
How do Confucian schools and Anglo schools differ? A latent profile analysis based on PISA 2015
Genetic factors, risk prediction and AI application of thrombotic diseases
Venous Thromboembolic Diseases: Diagnosis, Management and Thrombophilia Testing: Observations on NICE Guideline [NG158]
Marketing research in China during the 40-year reform and opening
Advances in CAR‐Engineered Immune Cell Generation: Engineering Approaches and Sourcing Strategies
Diagnostic and prognostic significance of lncRNA SOX2-OT in patients with carotid atherosclerosis
Hemophagocytic lymphohistiocytosis after COVID-19 vaccination
Venous Thromboembolism in COVID-19
Consolidative allogeneic hematopoietic stem cell transplantation after chimeric antigen receptor T-cell therapy for relapsed/refractory B-cell acute lymphoblastic leukemia: who? When? Why?
Biomarkers in individualized management of chimeric antigen receptor T cell therapy
Venous Thromboembolism in Kidney Diseases and Genetic Predisposition
Acute Total Occlusion of the Abdominal Aorta in an Elderly Patient with Atrial Fibrillation
How do Confucian schools and Anglo schools differ? A latent profile analysis based on PISA 2015
Genetic factors, risk prediction and AI application of thrombotic diseases
Venous Thromboembolic Diseases: Diagnosis, Management and Thrombophilia Testing: Observations on NICE Guideline [NG158]
Marketing research in China during the 40-year reform and opening
Advances in CAR‐Engineered Immune Cell Generation: Engineering Approaches and Sourcing Strategies
Diagnostic and prognostic significance of lncRNA SOX2-OT in patients with carotid atherosclerosis
Hemophagocytic lymphohistiocytosis after COVID-19 vaccination
Venous Thromboembolism in COVID-19
Consolidative allogeneic hematopoietic stem cell transplantation after chimeric antigen receptor T-cell therapy for relapsed/refractory B-cell acute lymphoblastic leukemia: who? When? Why?
Biomarkers in individualized management of chimeric antigen receptor T cell therapy
Venous Thromboembolism in Kidney Diseases and Genetic Predisposition
Acute Total Occlusion of the Abdominal Aorta in an Elderly Patient with Atrial Fibrillation
How do Confucian schools and Anglo schools differ? A latent profile analysis based on PISA 2015
Genetic factors, risk prediction and AI application of thrombotic diseases
Venous Thromboembolic Diseases: Diagnosis, Management and Thrombophilia Testing: Observations on NICE Guideline [NG158]
Marketing research in China during the 40-year reform and opening
Advances in CAR‐Engineered Immune Cell Generation: Engineering Approaches and Sourcing Strategies
Diagnostic and prognostic significance of lncRNA SOX2-OT in patients with carotid atherosclerosis
Hemophagocytic lymphohistiocytosis after COVID-19 vaccination
Venous Thromboembolism in COVID-19
Consolidative allogeneic hematopoietic stem cell transplantation after chimeric antigen receptor T-cell therapy for relapsed/refractory B-cell acute lymphoblastic leukemia: who? When? Why?